The nation of Zimbabwe has rejected a major American healthcare agreement worth $367m (272 million pounds) spanning five years over Washington's request for sensitive data.
The decision became public following a official document from December was disclosed, indicating that Head of State Emmerson Mnangagwa felt the agreement was "unbalanced".
A government spokesperson has since clarified that the US was demanding access to biological samples for research and profit while was unwilling to share the resulting advantages from any future vaccines.
"We must now begin the challenging and unfortunate task of scaling back our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had donated over $1.9bn in health funding to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has called for further negotiations to secure a deal acceptable to both sides so the nation's vital HIV treatment initiative can continue.
Wider Background
Zimbabwe's decision follows a similar situation in Kenya, where a high court blocked a similar deal with the US following concerns were filed about the security of Kenyans' health data.
After resuming the presidency recently, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
USAID had overseen aid for the American government, but Trump claimed its expenditure was "wasteful" and his administration was seeking government-to-government deals to boost transparency and responsibility.
As per statements, Sixteen African countries have so far agreed to similar agreements, representing more than $18.3bn in committed funds.
Specifics of the Rejected Deal
This assistance for Zimbabwe was intended to funded "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this cooperation might have yielded immense benefits for Zimbabwean communities, especially the 1.2 million currently on HIV treatment via US-supported initiatives," the Ambassador said.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"The proposal required Zimbabwe to surrender its genetic material and health information indefinitely, without any corresponding assurance of benefiting from any scientific breakthroughs – such as new medicines or tests – that could result from that provided information," Mangwana explained.
"Put simply, our country would supply the raw materials for scientific discovery without any certainty that the final treatments would be available to our people should a future disease outbreak arise."
National Interest and Global Health
Mangwana further pointed out that the American exit from the global health body and its pursuit of one-on-one deals were undermining systems previously established via the international health agency.
Mangwana cited its Pandemic Benefit-Sharing framework designed to deal with potential pandemics.
"This mechanism is designed to guarantee that when a nation contributes its information, the benefits – such as vaccines and treatments – are distributed fairly, not commercialised solely by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We welcome ongoing dialogue with our American counterparts on how future collaboration could be structured in a manner that respects the independence and dignity of both nations."
Health Experts Reaction
Medical experts expressed it understood the official position, but urged that talks need to persist considering much of the country's HIV programmes depended on external financing.
"If specific concerns arise, including those involving information security or agreement terms, these can often be resolved through technical clarification and mutually agreed protections," it said.
The situation underscores the ongoing challenges between accepting much-needed international aid and safeguarding a country's data in an ever more data-driven world.